Re-appointment of Whole Time Director and CFO of the Company, subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jenburkt Pharmaceuticals reported strong FY2026 results with revenue from operations rising 11.2% to ₹16,874 lakhs and profit after tax growing 8.3% to ₹3,474 lakhs. The Board declared a dividend of ₹20.70 per share (207%) for FY2025-26. Key leadership continuity was announced with the re-appointment of Shri Dilip H. Bhuta (74 years) as Whole Time Director and CFO for five years from April 2027 to March 2032, subject to shareholder approval at the September 2026 AGM. The company also appointed him as a director on rotation basis. Auditors D.R. Mehta & Associates issued an unmodified opinion on the financial statements. One-time exceptional charge of ₹395 lakhs was recorded due to revised labour codes impacting gratuity and leave liabilities.
The re-appointment of the CFO/Whole Time Director indicates leadership stability, which is positive for governance. Strong financial performance with 8% PAT growth and a 207% dividend payout signals healthy cash generation. The labour code impact created a one-time charge but underlying business remains robust.